The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Redox-regulated Turnover of Nrf2 Is Determined by at Least Two Separate Protein Domains, the Redox-sensitive Neh2 Degron and the Redox-insensitive Neh6 Degron
Open accessAbstract
The Nrf2 transcription factor is more rapidly turned over in cells grown under homeostatic conditions than in those experiencing oxidative stress. The variable turnover of Nrf2 is accomplished through the use of at least two degrons and its redox-sensitive interaction with the Kelch-repeat protein Keap1. In homeostatic COS1 cells, the Neh2 degron confers on Nrf2 a half-life of less than 10 min. Analyses of deletion mutants of a Gal4(HA)mNeh2 fusion protein and full-length mNrf2 indicate that full redox-sensitive Neh2 destabilizing activity depends upon two separate sequences within this N-terminal domain. The DIDLID element (amino acids 17-32) is indispensable for Neh2 activity and appears necessary to recruit a ubiquitin ligase to the fusion protein. A second motif within Neh2, the ETGE tetrapeptide (amino acids 79-82), allows the redox-sensitive recruitment of Nrf2 to Keap1. This interaction, which occurs only in homeostatic cells, enhances the capacity of the Neh2 degron to direct degradation by functioning downstream of ubiquitination mediated by the DIDLID element. By contrast with the situation under homeostatic conditions, the Neh2 degron is neither necessary nor sufficient to account for the characteristic half-life of Nrf2 in oxidatively stressed cells. Instead, the previously uncharacterized, redox-insensitive Neh6 degron (amino acids 329-379) is essential to ensure that the transcription factor is still appropriately turned over in stressed cells, albeit with an increased half-life of 40 min. A model can now be proposed to explain how the turnover of this protein adapts in response to alterations in cellular redox state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634
Self-citationZhang, D. D., & Hannink, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8137-8151.2003 · Cited by 1,480
Regulatory Mechanisms Controlling Gene Expression Mediated by the Antioxidant Response Element
Nguyen, T., Sherratt, P. J., & Pickett, C. B. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140229 · Cited by 1,236
Nrf2 Is a Direct PERK Substrate and Effector of PERK-Dependent Cell Survival
Cullinan, S. B., Zhang, D., Hannink, M., Arvisais, E., Kaufman, R. J., & Diehl, J. A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.20.7198-7209.2003 · Cited by 1,234
McMahon, M., Itoh, K., Yamamoto, M., & Hayes, J. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300931200 · Cited by 1,141
Venugopal, R., & Jaiswal, A. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14960 · Cited by 1,040
Wakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M.-I., Kobayashi, A., Yamamoto, M., Kensler, T. W., & Talalay, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307301101 · Cited by 986
Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ domain
Treier, M., Staszewski, L. M., & Bohmann, D. (1994) · Cell · doi:10.1016/s0092-8674(94)90502-9 · Cited by 923
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., O'Connor, T., & Yamamoto, M. (2003) · Genes to Cells · doi:10.1046/j.1365-2443.2003.00640.x · Cited by 816
Self-citation
Cited by
Loboda, A., Damulewicz, M., Pyza, E., Jozkowicz, A., & Dulak, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2223-0 · Cited by 2,632
Transcriptional Regulation by Nrf2
Tonelli, C., Chio, I. I. C., & Tuveson, D. A. (2018) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7342 · Cited by 2,192
The Nrf2 regulatory network provides an interface between redox and intermediary metabolism
Hayes, J. D., & Dinkova-Kostova, A. T. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.002 · Cited by 2,141
Self-citationThe KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis
Yamamoto, M., Kensler, T. W., & Motohashi, H. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2017 · Cited by 1,968
Self-citationNRF2, a Transcription Factor for Stress Response and Beyond
He, F., Ru, X., & Wen, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134777 · Cited by 1,820
Nrf2–Keap1 defines a physiologically important stress response mechanism
Motohashi, H., & Yamamoto, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.003 · Cited by 1,725
Self-citationNRF2 and the Hallmarks of Cancer
Rojo de la Vega, M., Chapman, E., & Zhang, D. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.022 · Cited by 1,672
The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway
Baird, L., & Yamamoto, M. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00099-20 · Cited by 1,542
Self-citationMolecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Self-citationTherapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Self-citationThe emerging role of the Nrf2–Keap1 signaling pathway in cancer
Jaramillo, M. C., & Zhang, D. D. (2013) · Genes & Development · doi:10.1101/gad.225680.113 · Cited by 1,297
Antioxidant responses and cellular adjustments to oxidative stress
Espinosa-Diez, C., Miguel, V., Mennerich, D., Kietzmann, T., Sánchez-Pérez, P., Cadenas, S., & Lamas, S. (2015) · Redox Biology · doi:10.1016/j.redox.2015.07.008 · Cited by 1,086
The cytoprotective role of the Keap1–Nrf2 pathway
Baird, L., & Dinkova-Kostova, A. T. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0674-5 · Cited by 1,027
Kobayashi, A., Kang, M.-I., Watai, Y., Tong, K. I., Shibata, T., Uchida, K., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.221-229.2006 · Cited by 933
Self-citationNRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer
Hayes, J. D., & McMahon, M. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.12.008 · Cited by 869
Self-citationKobayashi, M., & Yamamoto, M. (2006) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2006.01.007 · Cited by 856
Self-citationTebay, L. E., Robertson, H., Durant, S. T., Vitale, S. R., Penning, T. M., Dinkova-Kostova, A. T., & Hayes, J. D. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.021 · Cited by 837
“Keap1-independent degradation was first noted when it was recognized that Nrf2 mutant proteins lacking the Neh2 domain were not particularly stable [73].”
Self-citationMolecular mechanisms of Nrf2‐mediated antioxidant response
Li, W., & Kong, A. (2009) · Molecular Carcinogenesis · doi:10.1002/mc.20465 · Cited by 785
Rada, P., Rojo, A. I., Chowdhry, S., McMahon, M., Hayes, J. D., & Cuadrado, A. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01204-10 · Cited by 759
Self-citationTong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759
Self-citationSmall Molecule Modulators of Keap1‐ Nrf2‐ ARE Pathway as Potential Preventive and Therapeutic Agents
Magesh, S., Chen, Y., & Hu, L. (2012) · Medicinal Research Reviews · doi:10.1002/med.21257 · Cited by 760
“233 Some lipophilic thioethers, such as DAS (69), diallyl disulfide (DADS, 70), and diallyl trisulfide (DATS, 71), have been shown to upregulate the expression of detoxifying enzymes with inducing strength in the order of DATS > DADS > DAS, but the mechanism underlying ARE-inducing activity is poorly understood.”
BackgroundChowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A., & Hayes, J. D. (2013) · Oncogene · doi:10.1038/onc.2012.388 · Cited by 657
Self-citationStructure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling
Lo, S., Li, X., Henzl, M. T., Beamer, L. J., & Hannink, M. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601243 · Cited by 604
Structural basis of Keap1 interactions with Nrf2
Canning, P., Sorrell, F. J., & Bullock, A. N. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.034 · Cited by 592
Basic Principles and Emerging Concepts in the Redox Control of Transcription Factors
Brigelius-Flohé, R., & Flohé, L. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3534 · Cited by 576
Cancer Chemoprevention Mechanisms Mediated Through the Keap1–Nrf2 Pathway
Hayes, J. D., McMahon, M., Chowdhry, S., & Dinkova-Kostova, A. T. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3221 · Cited by 539
Self-citationModulating NRF2 in Disease: Timing Is Everything
Dodson, M., de la Vega, M. R., Cholanians, A. B., Schmidlin, C. J., Chapman, E., & Zhang, D. D. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021856 · Cited by 522
Salazar, M., Rojo, A. I., Velasco, D., de Sagarra, R. M., & Cuadrado, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513737200 · Cited by 521
Discovery of the Negative Regulator of Nrf2, Keap1: A Historical Overview
Itoh, K., Mimura, J., & Yamamoto, M. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3222 · Cited by 510
Self-citationRepression of the Antioxidant NRF2 Pathway in Premature Aging
Kubben, N., Zhang, W., Wang, L., Voss, T. C., Yang, J., Qu, J., Liu, G.-H., & Misteli, T. (2016) · Cell · doi:10.1016/j.cell.2016.05.017 · Cited by 489
“Given that progerin is a highly expressed long-lived protein (Boisvert et al., 2012), whereas NRF2 is low in abundance and short-lived (McMahon et al., 2004), progerin/NRF2 sequestration is expected to drastically reduce the availability of NRF2 for the formation of functional transcription factor…”
McMahon, M., Thomas, N., Itoh, K., Yamamoto, M., & Hayes, J. D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601119200 · Cited by 485
Self-citationThe Transcription Factor Nrf2 Is a Therapeutic Target against Brain Inflammation
Innamorato, N. G., Rojo, A. I., García-Yagüe, À. J., Yamamoto, M., de Ceballos, M. L., & Cuadrado, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.680 · Cited by 480
Self-citationRada, P., Rojo, A. I., Evrard-Todeschi, N., Innamorato, N. G., Cotte, A., Jaworski, T., Tobón-Velasco, J. C., Devijver, H., García-Mayoral, M. F., Van Leuven, F., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00180-12 · Cited by 474
Self-citationTwo-site substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism
Tong, K. I., Kobayashi, A., Katsuoka, F., & Yamamoto, M. (2006) · Biological Chemistry · doi:10.1515/bc.2006.164 · Cited by 473
Self-citationNrf2 in cancers: A double‐edged sword
Wu, S., Lu, H., & Bai, Y. (2019) · Cancer Medicine · doi:10.1002/cam4.2101 · Cited by 465
Sun, Z., Chin, Y. E., & Zhang, D. D. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01639-08 · Cited by 414
Activators and inhibitors of NRF2: a review of their potential for clinical development
Robledinos-Antón, N., Fernández-Ginés, R., Manda, G., & Cuadrado, A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9372182 · Cited by 413
Deshmukh, P., Unni, S., Krishnappa, G., & Padmanabhan, B. (2017) · Biophysical Reviews · doi:10.1007/s12551-016-0244-4 · Cited by 398
Canonical and non-canonical mechanisms of Nrf2 activation
Silva-Islas, C. A., & Maldonado, P. D. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.013 · Cited by 388
The Carboxy-Terminal Neh3 Domain of Nrf2 Is Required for Transcriptional Activation
Nioi, P., Nguyen, T., Sherratt, P. J., & Pickett, C. B. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.10895-10906.2005 · Cited by 381
Wang, H., Liu, K., Geng, M., Gao, P., Wu, X., Hai, Y., Li, Y., Li, Y., Luo, L., Hayes, J. D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3386 · Cited by 382
Self-citationThe Role of Keap1 in Cellular Protective Responses
Dinkova-Kostova, A. T., Holtzclaw, W. D., & Kensler, T. W. (2005) · Chemical Research in Toxicology · doi:10.1021/tx050217c · Cited by 376
Nioi, P., & Hayes, J. D. (2004) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.05.023 · Cited by 362
Self-citationKawai, Y., Garduño, L., Theodore, M., Yang, J., & Arinze, I. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.208173 · Cited by 353
The Arabidopsis Aux/IAA Protein Family Has Diversified in Degradation and Auxin Responsiveness
Dreher, K. A., Brown, J., Saw, R. E., & Callis, J. (2006) · The Plant Cell · doi:10.1105/tpc.105.039172 · Cited by 352
Nguyen, T., Sherratt, P. J., Nioi, P., Yang, C. S., & Pickett, C. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503074200 · Cited by 344
Cuadrado, A., Martín-Moldes, Z., Ye, J., & Lastres-Becker, I. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.540633 · Cited by 320
Abed, D. A., Goldstein, M., Albanyan, H., Jin, H., & Hu, L. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.008 · Cited by 319
NRF2 as a regulator of cell metabolism and inflammation in cancer
He, F., Antonucci, L., & Karin, M. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa039 · Cited by 318
Molecular Basis of Electrophilic and Oxidative Defense: Promises and Perils of Nrf2
Ma, Q., & He, X. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.004333 · Cited by 317
Redox Control of Microglial Function: Molecular Mechanisms and Functional Significance
Rojo, A. I., McBean, G., Cindric, M., Egea, J., López, M. G., Rada, P., Zarkovic, N., & Cuadrado, A. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5745 · Cited by 309
Targeting NRF2 signaling for cancer chemoprevention
Kwak, M.-K., & Kensler, T. W. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.08.028 · Cited by 305
Singh, S., Vrishni, S., Singh, B. K., Rahman, I., & Kakkar, P. (2010) · Free Radical Research · doi:10.3109/10715762.2010.507670 · Cited by 293
The Nrf2–ARE cytoprotective pathway in astrocytes
Vargas, M. R., & Johnson, J. A. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001094 · Cited by 291
Fukutomi, T., Takagi, K., Mizushima, T., Ohuchi, N., & Yamamoto, M. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01191-13 · Cited by 260
Self-citationStructural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3/β-TrCP
Cuadrado, A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.04.029 · Cited by 260
Crisman, E., Duarte, P., Dauden, E., Cuadrado, A., Rodríguez‐Franco, M. I., López, M. G., & León, R. (2023) · Medicinal Research Reviews · doi:10.1002/med.21925 · Cited by 257
Giudice, A., Arra, C., & Turco, M. C. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-738-9_3 · Cited by 256
The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment
Taguchi, K., & Yamamoto, M. (2020) · Cancers · doi:10.3390/cancers13010046 · Cited by 195
“elegans SKN-1 and in mice, rats and humans NRF2 [33].”
BackgroundSelf-citationKeap Calm, and Carry on Covalently
Wilson, A. J., Kerns, J. K., Callahan, J. F., & Moody, C. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400224q · Cited by 171
Zhu, J., Wang, H., Chen, F., Fu, J., Xu, Y., Hou, Y., Kou, H. H., Zhai, C., Nelson, M. B., Zhang, Q., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.09.010 · Cited by 162
Ooi, A., Dykema, K., Ansari, A., Petillo, D., Snider, J., Kahnoski, R., Anema, J., Craig, D., Carpten, J., Teh, B.-T., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3227 · Cited by 159
Dual roles of NRF2 in tumor prevention and progression: Possible implications in cancer treatment
Moon, E. J., & Giaccia, A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.11.009 · Cited by 160
Mann, G. E., Bonacasa, B., Ishii, T., & Siow, R. C. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.12.012 · Cited by 158
Electrophiles in Foods: The Current Status of Isothiocyanates and Their Chemical Biology
NAKAMURA, Y., & MIYOSHI, N. (2010) · Bioscience, Biotechnology, and Biochemistry · doi:10.1271/bbb.90731 · Cited by 143
A PGAM5–KEAP1–Nrf2 complex is required for stress-induced mitochondrial retrograde trafficking
O'Mealey, G. B., Plafker, K. S., Berry, W. L., Janknecht, R., Chan, J. Y., & Plafker, S. M. (2017) · Journal of Cell Science · doi:10.1242/jcs.203216 · Cited by 99
Zhuang, C., Wu, Z., Xing, C., & Miao, Z. (2017) · MedChemComm · doi:10.1039/c6md00500d · Cited by 84
Nrf2-mediated redox signaling in arsenic carcinogenesis: a review
Sinha, D., Biswas, J., & Bishayee, A. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0920-5 · Cited by 81
Knörr-Wittmann, C., Hengstermann, A., Gebel, S., Alam, J., & Müller, T. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.07.003 · Cited by 60
Metadata
- Authors
- McMahon, M., Thomas, N., Itoh, K., Yamamoto, M., & Hayes, J. D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-07
- Volume
- 279
- Issue
- 30
- Pages
- 31556-31567
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2076405456
- Cited by
- 404
- References
- 50
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.